bioAffinity Technologies, Inc. (BIAFW)

Market Cap	5.12M -56.2%
Revenue (ttm)	6.78M -27.7%
Net Income	-14.74M
EPS	-20.28
Shares Out	4.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.3100
Day's Range	n/a
52-Week Range	0.0525 - 0.8121
Beta	2.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2025

About BIAFW

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: BIAFW
• Website: https://www.bioaffinitytech.com